BioSpace News Archive

Genetown

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

VBI Vaccines Inc. announced that it has entered into definitive agreements for the sale and issuance of 2,272,728 common shares of VBI at an offering price of $0.88 per common share, in a registered direct offering priced at-the-market under the Nasdaq rules.

April 9, 2024
·
6 min read
Biotech Bay

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Bruton’s tyrosine kinase (BTK).

April 9, 2024
·
8 min read
Genetown

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting

Mural Oncology plc (Nasdaq: MURA) today shared poster presentations with pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at the American Association for Cancer Research (AACR) annual meeting taking place April 5-10 in San Diego, California.

April 9, 2024
·
6 min read
Business

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial ResultsConference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET

Oncocyte Corporation announced that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open.

April 9, 2024
·
1 min read
Drug Development

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK) today announced preclinical data demonstrating the therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy.

April 9, 2024
·
5 min read
BioForest

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

ImmuCell Corporation announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.

April 9, 2024
·
6 min read
Business

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that Joydeep Goswami has decided to leave Illumina.

April 9, 2024
·
3 min read
Business

GE HealthCare to Announce First Quarter 2024 Results on April 30, 2024

GE HealthCare, a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024.

April 9, 2024
·
1 min read
Drug Development

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.

April 9, 2024
·
7 min read
Business

Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time.

April 9, 2024
·
1 min read